In line with this, isolated circulating tumor cells (CTC) from patients with abiraterone- or Enz-resistant metastasis showed gene amplification of FOXA1 in more than 30% of CRPC patients [21], pinpointing the critical role of FOXA1 in emerging DRPC. Here, FOXA1 is linked to neoplasm.